Proliferative Diabetic Retinopathy Market
Global Proliferative Diabetic Retinopathy Market Size By Product Type (Anti-VEGF Agents, Corticosteroids), By Application (Hospitals, Clinics), By Geographic Scope And Forecast
Published Date: August - 2024 | Publisher: MIR | No of Pages: 320 | Industry: latest updates trending Report | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Free Sample Ask for Discount Request CustomizationProliferative Diabetic Retinopathy Market Size And Forecast
Proliferative Diabetic Retinopathy Market size was valued at USD 2513.07 Million in 2022 and is projected to reach USD 9037.95 Million by 2030, growing at a CAGR of 17.35% from 2023 to 2030.
The rising incidence of diabetes, the increasing geriatric population base, and the rising numbers of diabetes-related loss of vision are anticipated to propel the growth of the Global Proliferative Diabetic Retinopathy Market. Overweight, changes in lifestyle, and intake of unhealthy foods are some of the factors that are likely to drive the market in the coming years. The Global Proliferative Diabetic Retinopathy Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors playing a substantial role in the market.
Key Players
The “Global Proliferative Diabetic Retinopathy Market” study report will provide valuable insight with an emphasis on the global market including some of the major players such as Merck KGaA, c, Intas Pharmaceuticals, Genentech Inc. (Roche Holdings), Valeant Pharmaceuticals International, Pfizer, Allergan Plc, Santen Pharmaceutical, Regeneron Pharmaceuticals
Global Proliferative Diabetic Retinopathy Market Definition
Since there are insufficient insulin hormones to metabolize blood sugar, diabetes is a chronic condition that never goes away. A diabetic patient who has an eye condition is said to have diabetic retinopathy. Proliferative The most severe form of diabetic eye damage is called diabetic retinopathy. The retina starts to develop new blood vessels at this stage. This process is called neovascularization. Frequently, the vitreous is bled into by these undesirable veins. If they bleed only a tiny bit, we only see a few small black floaters, but if they bleed a lot, eyesight may be completely obscured. PDR is a significant medical disorder that can impair both central and peripheral (side) vision if it is not promptly addressed.
It is identified using tests like fluorescein angiography and optical coherence tomography, and it is treated with intraocular steroid injection, laser therapy, and vitrectomy. The most prevalent symptoms of this disorder are blurred vision, dark or empty areas in the vision, fluctuating vision, impeded color vision, and loss of vision. The global proliferative diabetic retinopathy is classified as Non-Proliferative Diabetic Retinopathy( NPDR) and Proliferative Diabetic Retinopathy. Non-proliferative retinopathy is recognized as the early stage of DR when there is no abnormal enlargement of blood vessels (proliferation). NPDR deteriorates the walls of your retinal blood vessels.
This causes ‘micro aneurysms’ from the walls of the tiny blood vessels, starting to cause fluid and blood to leak into the retina. Proliferative Diabetic Retinopathy is the stage, where the previously damaged blood vessels have sealed off, enhancing the formation of new, abnormal blood vessels inside the retina, that are most prone to leaking blood and fluid into a clear, jelly-like particle that fills the central area of the eye. Diabetic retinopathy treatments depend on the severity of the condition and may include vitrectomy, intraocular injections, anti-VEGF drugs, and laser treatment. The disease can be resisted by managing diabetes, trying to control blood glucose levels, and paying enough attention to vision problems.
Global Proliferative Diabetic Retinopathy Market Overview
The rising incidence of diabetes, the increasing geriatric population base, and the growing incidence of diabetes-related vision loss are expected to dominate the growth Proliferative Diabetic Retinopathy Market. The increase in obesity, changes in lifestyle, and global intake of unhealthy foods are some of the factors that are expected to drive the market during the forecast period. Moreover, the general public has become more aware of the various treatment options and the privileges of early diagnosis of DR. As an outcome, advanced technological processes, and equipment, including improved ophthalmic diagnostic and surgical equipment, are now widely utilized leading to an increase in the growth of the Global Proliferative Diabetic Retinopathy Market.
The rising geriatric worldwide, as well as their elevated risk of chronic conditions such as diabetes, cardiovascular problems, and sleep problems, drive future growth to a considerable extent. The prospective restraints that hindered the entire market are a lack of reliable diagnosis, a lack of availability of skilled doctors and specialists, and adverse effects of treatment. Furthermore, surgical tools have improved precision, which increases the success rate of surgeries. As an outcome, the existence of such upgraded ophthalmic devices and systems has made possible medical and treatment procedures, which has a productive impact on industry growth.
However, issues and unfavorable consequences related to medications recommended to treat diabetic retinopathy may restrain market expansion. The future rise in diabetic retinopathy is driven by technological advancements in ophthalmic surgery, diagnostic, and treatment instruments throughout the anticipated period. Medical professionals can make better judgments because optical coherence tomography and other technologically sophisticated diagnostic tools provide higher-quality cross-sectional pictures. Additionally, surgical instruments are now more accurate, which raises the success rates of operations. Thus, the availability of such modernized ophthalmic gadgets has simplified diagnostic and therapeutic processes, favorably affecting the expansion of the market for proliferative diabetic retinopathy.
Global Proliferative Diabetic Retinopathy Market Segmentation Analysis
The Global Proliferative Diabetic Retinopathy Market is Segmented on the basis of Application Product Type, And Geography.
Proliferative Diabetic Retinopathy Market, By Product Type
- Anti-VEGF Agents
- Corticosteroids
- Other
Based on Product Type, The market is segmented into Anti-VEGF Agents, Corticosteroids, and Others. The Anti-VEGF agents are expected to grow the highest market during the forecasted period because this segment is needed to manage its dominance all throughout the forecast period, owing to the growing applications of anti-VEGF drugs including such Eylea, Macugen, Lucentis, and Avastin in the treatment of mild-to-moderate cases of diabetic retinopathy, which is among the main factors responsible for the segment’s growth.
Proliferative Diabetic Retinopathy Market, By Application
- Hospitals
- Clinics
- Others
Based on Application, The market is segmented into Hospitals, Clinics, and Others. Hospitals lead to the highest growth of global proliferative diabetic retinopathy during the forecasted period because the government funds the hospitals in the public healthcare system. As an outcome, these hospitals can manage to accept technologically advanced devices for ophthalmic surgeries, which profits growth of this segment.
Proliferative Diabetic Retinopathy Market, By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
On the basis of Regional Analysis, the Proliferative Diabetic Retinopathy Market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America is projected to be the highest-growing market over the forecasted period. Bayer AG is among the leading companies in the United States, and has captured the largest market share by introducing high-quality medications for diabetic retinopathy. As an outcome, the huge number of diabetes patients is anticipated to produce to growing market all across an entire region.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players.
Key Developments
- In April 2023, Genentech, a subsidiary of the Roche Group, said that 30 abstracts at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held from April 23–27 in New Orleans, LA, would showcase new evidence for its marketed and experimental treatments.
- In September 2021, Intas Pharmaceuticals Ltd. (Intas) and Axantia Holding (Axantia), a significant Middle Eastern pharmaceutical organisation, have entered into an exclusive licence and supply agreement for Ranibizumab (a biosimilar to Lucentis®), which is manufactured by Pharma International Pharmaceutical & Chemical Manufacturing Co. Ltd. and Med City Pharmaceutical Industries. Axantia will register Ranibizumab, hold the marketing licence, and promote it in select regions, including Saudi Arabia, Jordan, Iraq, Lebanon, and the GCC nations. A biosimilar of Lucentis® that Intas has created is now undergoing a Phase III worldwide trial in preparation for submission to the EMA and the US, among other important nations.
Ace Matrix Analysis
The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
Market Attractiveness
The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Proliferative Diabetic Retinopathy Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
Porter’s Five Forces
The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. Porter’s five forces model can be used to assess the competitive landscape in the Global Proliferative Diabetic Retinopathy Market, gauge the attractiveness of a certain sector, and assess investment possibilities.
Report Scope
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| STUDY PERIOD |
2020-2030 |
| BASE YEAR |
2024 |
| FORECAST PERIOD |
2024-2030 |
| HISTORICAL PERIOD |
2020-2024 |
| UNIT |
Value (USD Million) |
| KEY COMPANIES PROFILED |
Merck KGaA, Allergan Plc, Intas Pharmaceuticals, Genentech Inc. (Roche Holdings), Valeant Pharmaceuticals International, Pfizer, Allergan Plc, Santen Pharmaceutical, Regeneron Pharmaceuticals |
| SEGMENTS COVERED |
|
| CUSTOMIZATION SCOPE |
Free report customization (equivalent to up to +4 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Research Methodology of Market Research
What's inside a industry report?
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Related Reports
- Global Cognitive Data Management Market Size By Deployment Type, By Organization Size, By Business Function, By Geograph...
- Global DDoS Protection And Mitigation Market Size By Type of Solution, By Deployment Mode, By Organization Size, By Geog...
- Incident and Emergency Management Market Size By Solution (Perimeter Intrusion Detection, Fire And HAZMAT Solutions), By...
- Global Metallocene Polyethylene Market Size By Type, By Application, By End-User Industry, By Geographic Scope And Forec...
- Global Wireless Gas Detection Market Size By Component, By Technology, By Geographic Scope And Forecast
- Global Security Control Room Market Size By Technology, By Application, By End-User Industry, By Geographic Scope And Fo...
Table of Content
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Management
1.2.3. Regional Scope
1.2.4. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type Outlook
2.2.2. Management Outlook
2.2.3. Regional Outlook
2.3. Competitive Insights
Chapter 3. Diabetic Retinopathy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Diabetic Retinopathy Market Analysis tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
Chapter 4. Diabetic Retinopathy Market: Type Estimates & Trend Analysis
4.1. Type Segment Dashboard
4.2. Diabetic Retinopathy Market: Type Movement Analysis
4.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Proliferative Diabetic Retinopathy
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Non-Proliferative Diabetic Retinopathy
4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. Diabetic Retinopathy Market: Management Estimates & Trend Analysis
5.1. Management Segment Dashboard
5.2. Diabetic Retinopathy Market: Management Movement Analysis
5.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Management, 2018 to 2030 (USD Million)
5.4. Anti-VEGF
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Intraocular Steroid Injection
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6. Laser Surgery
5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.7. Vitrectomy
5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. Diabetic Retinopathy Market: Regional Estimates & Trend Analysis
6.1. Regional Market Dashboard
6.2. Regional Market Share Analysis, 2024 & 2030
6.3. Continuous Bioprocessing Market By Region: Key Takeaways
6.4. North America
6.4.1. U.S.
6.4.1.1. Key Country Dynamics
6.4.1.2. Regulatory Framework/ Reimbursement Structure
6.4.1.3. Competitive Scenario
6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.2. Canada
6.4.2.1. Key Country Dynamics
6.4.2.2. Regulatory Framework/ Reimbursement Structure
6.4.2.3. Competitive Scenario
6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.3. Mexico
6.4.3.1. Key Country Dynamics
6.4.3.2. Regulatory Framework/ Reimbursement Structure
6.4.3.3. Competitive Scenario
6.4.3.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Europe
6.5.1. UK
6.5.1.1. Key Country Dynamics
6.5.1.2. Regulatory Framework/ Reimbursement Structure
6.5.1.3. Competitive Scenario
6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.2. Germany
6.5.2.1. Key Country Dynamics
6.5.2.2. Regulatory Framework/ Reimbursement Structure
6.5.2.3. Competitive Scenario
6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.3. France
6.5.3.1. Key Country Dynamics
6.5.3.2. Regulatory Framework/ Reimbursement Structure
6.5.3.3. Competitive Scenario
6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.4. Italy
6.5.4.1. Key Country Dynamics
6.5.4.2. Regulatory Framework/ Reimbursement Structure
6.5.4.3. Competitive Scenario
6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.5. Spain
6.5.5.1. Key Country Dynamics
6.5.5.2. Regulatory Framework/ Reimbursement Structure
6.5.5.3. Competitive Scenario
6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.6. Denmark
6.5.6.1. Key Country Dynamics
6.5.6.2. Regulatory Framework/ Reimbursement Structure
6.5.6.3. Competitive Scenario
6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key Country Dynamics
6.5.7.2. Regulatory Framework/ Reimbursement Structure
6.5.7.3. Competitive Scenario
6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.8. Norway
6.5.8.1. Key Country Dynamics
6.5.8.2. Regulatory Framework/ Reimbursement Structure
6.5.8.3. Competitive Scenario
6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key Country Dynamics
6.6.1.2. Regulatory Framework/ Reimbursement Structure
6.6.1.3. Competitive Scenario
6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.2. China
6.6.2.1. Key Country Dynamics
6.6.2.2. Regulatory Framework/ Reimbursement Structure
6.6.2.3. Competitive Scenario
6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.3. India
6.6.3.1. Key Country Dynamics
6.6.3.2. Regulatory Framework/ Reimbursement Structure
6.6.3.3. Competitive Scenario
6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.4. South Korea
6.6.4.1. Key Country Dynamics
6.6.4.2. Regulatory Framework/ Reimbursement Structure
6.6.4.3. Competitive Scenario
6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.5. Thailand
6.6.5.1. Key Country Dynamics
6.6.5.2. Regulatory Framework/ Reimbursement Structure
6.6.5.3. Competitive Scenario
6.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamics
6.6.6.2. Regulatory Framework/ Reimbursement Structure
6.6.6.3. Competitive Scenario
6.6.6.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key Country Dynamics
6.7.1.2. Regulatory Framework/ Reimbursement Structure
6.7.1.3. Competitive Scenario
6.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7.2. Argentina
6.7.2.1. Key Country Dynamics
6.7.2.2. Regulatory Framework/ Reimbursement Structure
6.7.2.3. Competitive Scenario
6.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key Country Dynamics
6.8.1.2. Regulatory Framework/ Reimbursement Structure
6.8.1.3. Competitive Scenario
6.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.2. Saudi Arabia
6.8.2.1. Key Country Dynamics
6.8.2.2. Regulatory Framework/ Reimbursement Structure
6.8.2.3. Competitive Scenario
6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.3. UAE
6.8.3.1. Key Country Dynamics
6.8.3.2. Regulatory Framework/ Reimbursement Structure
6.8.3.3. Competitive Scenario
6.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.4. Kuwait
6.8.4.1. Key Country Dynamics
6.8.4.2. Regulatory Framework/ Reimbursement Structure
6.8.4.3. Competitive Scenario
6.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key Company Heat Map Analysis, 2024
7.4. Company Profiles
7.4.1. Bayer AG
7.4.1.1. Company Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. AbbVie Inc.
7.4.2.1. Company Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Novartis AG
7.4.3.1. Company Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Oxurion NV.
7.4.4.1. Company Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Sirnaomics, Inc.
7.4.5.1. Company Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Alimera Sciences
7.4.6.1. Company Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Ampio Pharmaceuticals Inc.
7.4.7.1. Company Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. BCN Peptides
7.4.8.1. Company Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Kowa Company, Ltd.
7.4.9.1. Company Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Genentech, Inc.
7.4.10.1. Company Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 North America diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
Table 3 North America diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 4 North America diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 5 U.S. diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 6 U.S. diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 7 Canada diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 8 Canada diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 9 Mexico diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 10 Mexico diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 11 Europe diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
Table 12 Europe diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 13 Europe diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 14 UK diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 15 UK diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 16 Germany diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 17 Germany diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 18 France diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 19 France diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 20 Italy diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 21 Italy diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 22 Spain diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 23 Spain diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 24 Denmark diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 25 Denmark diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 26 Sweden diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 27 Sweden diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 28 Norway diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 29 Norway diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 30 Asia Pacific diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
Table 31 Asia Pacific diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 32 Asia Pacific diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 33 Japan diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 34 Japan diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 35 China diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 36 China diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 37 India diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 38 India diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 39 South Korea diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 40 South Korea diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 41 Thailand diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 42 Thailand diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 43 Australia diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 44 Australia diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 45 Latin America diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
Table 46 Latin America diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 47 Latin America surgical ablation market, by management, 2018 - 2030 (USD Million)
Table 48 Brazil diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 49 Brazil diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 50 Argentina diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 51 Argentina diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 52 MEA diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
Table 53 MEA diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 54 MEA diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 55 South Africa diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 56 South Africa diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 59 UAE diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 60 UAE diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 61 Kuwait diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 62 Kuwait diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Diabetic retinopathy market: market outlook
Fig. 10 Diabetic retinopathy competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 Diabetic retinopathy market driver impact
Fig. 16 Diabetic retinopathy market restraint impact
Fig. 17 Diabetic retinopathy market strategic initiatives analysis
Fig. 18 Diabetic retinopathy market: Type movement analysis
Fig. 19 Diabetic retinopathy market: Type outlook and key takeaways
Fig. 20 Proliferative diabetic retinopathy market estimates and forecast, 2018 - 2030
Fig. 21 Non-proliferative diabetic retinopathy estimates and forecast, 2018 - 2030
Fig. 22 Diabetic retinopathy market: Management movement analysis
Fig. 23 Diabetic retinopathy market: Management outlook and key takeaways
Fig. 24 Anti-VEGF market estimates and forecasts, 2018 - 2030
Fig. 25 Intraocular steroid injection market estimates and forecasts,2018 - 2030
Fig. 26 Laser surgery market estimates and forecasts, 2018 - 2030
Fig. 27 Vitrectomy market estimates and forecasts, 2018 - 2030
Fig. 28 Global diabetic retinopathy market: regional movement analysis
Fig. 29 Global diabetic retinopathy market: regional outlook and key takeaways
Fig. 30 North America market estimates and forecasts, 2018 - 2030
Fig. 31 U.S. market estimates and forecasts, 2018 - 2030
Fig. 32 Canada market estimates and forecasts, 2018 - 2030
Fig. 33 Mexico market estimates and forecasts, 2018 - 2030
Fig. 34 Europe market estimates and forecasts, 2018 - 2030
Fig. 35 UK market estimates and forecasts, 2018 - 2030
Fig. 36 Germany market estimates and forecasts, 2018 - 2030
Fig. 37 France market estimates and forecasts, 2018 - 2030
Fig. 38 Italy market estimates and forecasts, 2018 - 2030
Fig. 39 Spain market estimates and forecasts, 2018 - 2030
Fig. 40 Denmark market estimates and forecasts, 2018 - 2030
Fig. 41 Sweden market estimates and forecasts, 2018 - 2030
Fig. 42 Norway market estimates and forecasts, 2018 - 2030
Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 44 Japan market estimates and forecasts, 2018 - 2030
Fig. 45 China market estimates and forecasts, 2018 - 2030
Fig. 46 India market estimates and forecasts, 2018 - 2030
Fig. 47 South Korea market estimates and forecasts, 2018 - 2030
Fig. 48 Thailand market estimates and forecasts, 2018 - 2030
Fig. 49 Australia market estimates and forecasts, 2018 - 2030
Fig. 50 Latin America market estimates and forecasts, 2018 - 2030
Fig. 51 Brazil market estimates and forecasts, 2018 - 2030
Fig. 52 Argentina market estimates and forecasts, 2018 - 2030
Fig. 53 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 54 South Africa market estimates and forecasts, 2018 - 2030
Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 56 UAE market estimates and forecasts, 2018 - 2030
Fig. 57 Kuwait market estimates and forecasts, 2018 - 2030
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy